Disagree
Home Beligas Pharmaceuticals Beligas Pharmaceuticals
Retho-Cialis 25
Retho-Cialis 25 - Beligas Pharmaceuticals

Retho-Cialis 25 - Beligas Pharmaceuticals

Brand:
Category:
Substance:
Dosage:
25 mg/tab
Package:
50 tablets
Price:
0
See options
Product Overview
With a half-life that exceeds most similar compounds, Tadalafil provides lasting effects that go beyond its original medical use. It enhances blood circulation by relaxing smooth muscle tissue through the inhibition of the PDE5 enzyme. Athletes began using it informally for its supportive role in training recovery and performance. Some reported increased vascularity and improved nutrient transport to working muscles, especially during intense workout periods. Its appeal lies in effectiveness without affecting hormone levels.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Retho-Cialis 25 by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.

Explore More Products
FAQ
How does Tadalafil support blood flow enhancement?
Tadalafil increases nitric oxide-mediated vasodilation by inhibiting PDE5, leading to improved circulation.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Why do some athletes use Tadalafil outside of its medical use?
Tadalafil may enhance vascularity and performance by boosting nutrient delivery to working muscles.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Is Tadalafil active longer than similar compounds?
Yes, Tadalafil offers a longer duration of action—up to 36 hours making it more convenient than shorter-acting PDE5 inhibitors.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.